Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.